Detalhe da pesquisa
1.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Blood
; 141(14): 1675-1684, 2023 04 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36542826
2.
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Lancet
; 399(10343): 2294-2308, 2022 06 18.
Artigo
Inglês
| MEDLINE | ID: mdl-35717989
3.
Plain language summary of the TRANSFORM study primary analysis results: liso-cell as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Future Oncol
; : 1-11, 2024 Mar 28.
Artigo
Inglês
| MEDLINE | ID: mdl-38547003
4.
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL.
Blood Adv
; 6(23): 5969-5979, 2022 12 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36149968